Article · Wikipedia archive · Last revised Jul 9, 2026

Fosopamine

Fosopamine (INNTooltip International Nonproprietary Name; developmental code names SIM-2055, Z-2055; also known as fosfenamine or N-methyldopamine 4-O-phosphate) is a dopamine receptor agonist of the phenethylamine and catecholamine families which was under development for the treatment of hypertension but was never marketed. It is taken orally. Fosopamine is a prodrug of epinine (N-methyldopaine) and is said to be selectively metabolized into epinine in the kidneys. The drug was being developed by AstraZeneca and Zambon Group SpA. It reached phase 2 clinical trials prior to the discontinuation of its development.

Last revised
Jul 9, 2026
Read time
≈ 1 min
Length
181 w
Citations
8
Source
Fosopamine
Clinical data
Other namesFosfenamine; N-Methyldopamine 4-O-phosphate; Epinine 4-O-phosphate; SIM-2055; Z-2055
Routes of
administration
Oral1
Drug classDopamine receptor agonist1
Identifiers
  • [2-hydroxy-4-[2-(methylamino)ethyl]phenyl] dihydrogen phosphate
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC9H14NO5P
Molar mass247.187 g·mol−1
3D model (JSmol)
  • CNCCC1=CC(=C(C=C1)OP(=O)(O)O)O
  • InChI=1S/C9H14NO5P/c1-10-5-4-7-2-3-9(8(11)6-7)15-16(12,13)14/h2-3,6,10-11H,4-5H2,1H3,(H2,12,13,14)
  • Key:WHEGQKBWPSOMHG-UHFFFAOYSA-N

Fosopamine (INNTooltip International Nonproprietary Name; developmental code names SIM-2055, Z-2055; also known as fosfenamine or N-methyldopamine 4-O-phosphate) is a dopamine receptor agonist of the phenethylamine and catecholamine families which was under development for the treatment of hypertension but was never marketed.12 It is taken orally.1 Fosopamine is a prodrug of epinine (N-methyldopaine) and is said to be selectively metabolized into epinine in the kidneys.3 The drug was being developed by AstraZeneca and Zambon Group SpA.1 It reached phase 2 clinical trials prior to the discontinuation of its development.1

See also

See also

References

References

  1. "Fosopamine". AdisInsight. 7 April 1999. Retrieved 27 February 2025.
  2. Negwer M (1994). Organic-chemical Drugs and Their Synonyms: (an International Survey). Akademie Verlag. ISBN 978-3-05-500156-7. Retrieved 27 February 2025.
  3. Supuran C, Angeli A, Tanini D (2024). Advances in Prodrugs: Design and Therapeutic Applications. Elsevier. p. 296. ISBN 978-0-443-15634-2. Retrieved 27 February 2025.